Wednesday, May 11th, 2016 - WiseGuyReports

The report ‘Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2016’ provides comprehensive information on the therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects.

 

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

 

Complete report details @ https://www.wiseguyreports.com/reports/hormone-refractory-castration-resistant-androgen-independent-cancer-pipeline-review-h1-2016

 

Companies included in this report are:

  • Menarini Industrie Farmaceutiche Riunite Srl
  • AB Science SA
  • AbbVie Inc.
  • Adamis Pharmaceuticals Corporation
  • Advaxis, Inc.
  • Aeterna Zentaris Inc.
  • Alethia Biotherapeutics Inc.
  • Ambrx, Inc.
  • Amgen Inc.
  • AnGes MG, Inc.
  • Angion Biomedica Corp.
  • Aphios Corporation
  • Armour Therapeutics Inc.
  • Arno Therapeutics, Inc.
  • Arrowhead Research Corporation
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • ATLAB Pharma SAS
  • Bavarian Nordic A/S
  • Bayer AG
  • Beta Pharma, Inc.
  • BIND Therapeutics, Inc.
  • Bio-Cancer Treatment International Limited
  • Biscayne Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CellCentric Ltd
  • Celldex Therapeutics, Inc.
  • Corcept Therapeutics Incorporated
  • Corvus Pharmaceuticals, Inc.
  • CureVac GmbH
  • CytoVac A/S
  • DexTech Medical AB
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • Enceladus Pharmaceuticals BV
  • Endo Pharmaceuticals Inc.
  • EndoCeutics, Inc.
  • Endocyte, Inc.
  • Errant Gene Therapeutics, LLC
  • ESSA Pharma Inc
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Corporation
  • G1 Therapeutics, Inc.
  • Genentech, Inc.
  • Genmab A/S
  • GenSpera, Inc.
  • Gilead Sciences, Inc.
  • Glactone Pharma AB
  • GlaxoSmithKline Plc
  • GTx, Inc.
  • Hybrigenics S.A.
  • Immunomedics, Inc.
  • Incuron, LLC
  • Io Therapeutics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Johnson & Johnson
  • Jyant Technologies, Inc.
  • Kura Oncology, Inc.
  • Mediolanum farmaceutici S.p.A.
  • Medivation, Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • NewLink Genetics Corporation
  • Novartis AG
  • Oncogenex Pharmaceuticals, Inc.
  • Oncolytics Biotech Inc.
  • Orion Oyj
  • Orphagen Pharmaceuticals, Inc.
  • Panacela Labs, Inc.
  • Pfizer Inc.
  • Progenics Pharmaceuticals, Inc.
  • Sanofi
  • Sotio a.s.
  • Supratek Pharma Inc.
  • Synta Pharmaceuticals Corp.
  • Taiho Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Tesaro, Inc.
  • Tiltan Pharma Ltd.
  • Tokai Pharmaceuticals, Inc.
  • TRACON Pharmaceuticals, Inc.
  • UbiVac, LLC
  • Viralytics Ltd.

 

Request a sample report @ https://www.wiseguyreports.com/sample-request/hormone-refractory-castration-resistant-androgen-independent-cancer-pipeline-review-h1-2016  

 

 

Scope

- The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 
- The report reviews pipeline therapeutics for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics and enlists all their major and minor projects 
- The report assesses Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

 

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=464937

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

[email protected]

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

 

File Library

Contact Profile

WiseGuyReports


Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Our Market Research Reports and Consulting Services 

Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. The Wise Guy Reports team prides itself in being the chosen source for market research reports, report customizations services, and other ancillary services such as a Newsletter service and corporate service for large organizations.

Hundreds of large and small organizations across virtually every industry sector worldwide are currently reaping rich dividends from the sharp insights provided by market research reports sourced through Wise Guy Reports. 

Gaining an insight into emerging trends, opportunities and potential threats is key to long-term sustenance in a competitive environment. The handpicked collection of market research reports on Wise Guy Reports is centred on this proven principle.


Norah Trent
P: +44 208 133 9349
M: +1 646 845 9349
W: www.wiseguyreports.com/

Keywords

Hormone Refractory Prostate Cancer Therapeutic market trend, Hormone Refractory Prostate Cancer Therapeutic market segmentation, Hormone Refractory Prostate Cancer Therapeutic market analysis, Hormone Refractory Prostate Cancer Therapeutic marke

Categories

Newsrooms

Sharing

More Formats